Skip to content
April 28, 2026

US FDA Accepts New Drug Application for Cullinan Therapeutics’ Zipalertinib for Treatment of Non-Small Cell Lung Cancer

You are about to leave MPM BioImpact's website. MPM BioImpact is not responsible for the content on other companies' websites.

Cancel Continue